Ads
-
Related paper
- Stable and Bio-equivalent Formulation of HMG-CoA reductase inhibitor: Atorvastatin Calcium
- FORMULATION AND EVALUATION OF NOVEL MICROEMULSIONS OF ATORVASTATIN CALCIUM TRIHYDRATE
- FORMULATION AND EVALUATION OF SUSTAINED RELEASE MICROSPHERES OF ROSIN CONTAINING ATORVASTATIN CALCIUM
- FORMULATION AND EVALUATION OF GASTRO-RETENTIVE DRUG DELIVERY SYSTEM OF ATORVASTATIN CALCIUM
- Neopterin - inhibitor of dihydrofolate reductase and hypothetical action in the human body
- Is HMG-Co A Reductase Inhibitor Use Associated with Improved Outcomes in Patients Undergoing Colorectal Cancer Resection?
- EVALUATION SOME OF IMMUNOLOGICAL PARAMETERS IN BENIGN PROSTATIC HYPERPLASIA PATIENTS TREATED WITH 5 ALPH-REDUCTASE INHIBITOR (FINASTERIDE)
- STANDARDIZATION, FORMULATION AND EVALUATION OF COX-2 INHIBITOR FORMULATION IN SEMISOLID DOSAGE FORM SUITABLE FOR USE IN MUSCULOSKELETAL DISORDERS
- HMG-CoA reductase inhibitor, rosuvastatin averted carbon tetrachloride-induced oxidative stress, inflammation and fibrosis in the liver of rats
- Efficacy and tolerability of atorvastatin as add on therapy in the treatment of chronic stable (moderate-severe) asthma for a duration of 8 weeks